Texas Yale Capital Corp. Acquires 2,358 Shares of Johnson & Johnson $JNJ

Texas Yale Capital Corp. grew its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 6.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 38,395 shares of the company’s stock after purchasing an additional 2,358 shares during the quarter. Texas Yale Capital Corp.’s holdings in Johnson & Johnson were worth $10,165,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Outlook Capital Management LLC acquired a new position in Johnson & Johnson during the second quarter worth $28,000. Navigoe LLC raised its holdings in Johnson & Johnson by 60.4% during the third quarter. Navigoe LLC now owns 146 shares of the company’s stock valued at $38,000 after buying an additional 55 shares in the last quarter. Matrix Trust Co raised its holdings in Johnson & Johnson by 56.2% during the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after buying an additional 54 shares in the last quarter. Montgomery Financial Services LLC acquired a new stake in shares of Johnson & Johnson in the second quarter worth about $43,000. Finally, Hanseatic Management Services Inc. acquired a new stake in shares of Johnson & Johnson in the third quarter worth about $52,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Trending Headlines about Johnson & Johnson

These are some of the JNJ headlines that stood out recently:

  • Positive Sentiment: J&J announced the first U.S. commercial installation of its OTTAVA surgical robot at a Houston hospital, an early step in bringing the platform to market and expanding its surgical-technology business. Article
  • Positive Sentiment: The company submitted an FDA application to expand CAPLYTA’s use to bipolar I mania or mixed episodes, supported by two positive Phase 3 studies. Approval is not guaranteed, but another indication could broaden the drug’s growth potential. Article
  • Neutral Sentiment: JPMorgan raised its JNJ price target to $300 from $285 but kept a “neutral” rating, signaling a higher valuation estimate without a change in its overall recommendation. Analyst rating

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on JNJ. Royal Bank Of Canada lowered their price objective on Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating on the stock in a report on Wednesday, October 14th. Guggenheim restated a “buy” rating and issued a $287.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 7th. Morgan Stanley decreased their target price on Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating for the company in a research report on Thursday, October 15th. Weiss Ratings downgraded Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a report on Friday, October 23rd. Finally, JPMorgan Chase & Co. lifted their price target on shares of Johnson & Johnson from $285.00 to $300.00 and gave the company a “neutral” rating in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $276.54.

Get Our Latest Report on Johnson & Johnson

Johnson & Johnson Stock Up 1.3%

Johnson & Johnson stock opened at $270.54 on Friday. The firm has a market cap of $651.27 billion, a price-to-earnings ratio of 40.99, a P/E/G ratio of 2.79 and a beta of 0.22. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. Johnson & Johnson has a fifty-two week low of $199.90 and a fifty-two week high of $290.25. The firm has a fifty day moving average price of $267.53 and a two-hundred day moving average price of $250.98.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.06. The company had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The firm’s revenue was up 5.9% compared to the same quarter last year. During the same period last year, the business posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, analysts forecast that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be paid a dividend of $1.34 per share. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 annualized dividend and a yield of 2.0%. Johnson & Johnson’s dividend payout ratio is presently 81.21%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Elizabeth Forminard sold 13,072 shares of the firm’s stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $284.39, for a total value of $3,717,546.08. Following the sale, the executive vice president owned 16,994 shares of the company’s stock, valued at $4,832,923.66. This trade represents a 43.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. This trade represents a 56.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.